Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298139273> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4298139273 endingPage "239" @default.
- W4298139273 startingPage "239" @default.
- W4298139273 abstract "239 Background: Abemaciclib is a selective cyclin-dependent kinase 4 & 6 inhibitor, approved for hormone receptor-positive (HR+), HER2- advanced breast cancer (aBC) as monotherapy or in combination with fulvestrant or nonsteroidal aromatase inhibitors. Abemaciclib is also approved in combination with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high risk early BC (EBC). Despite demonstrated efficacy and overall tolerable safety profile, some pts discontinue abemaciclib without a prior dose reduction, highlighting the need for appropriate symptom management. This analysis aims to provide guidance on management of AEs for pts with aBC or EBC receiving abemaciclib. Methods: Study level data were collected for publications related to MONARCH 1, 2, and 3, and monarchE clinical trials. Endpoints included incidence of any-grade AEs, dose modifications, and discontinuations. Data on monitoring of AEs were also extracted. Results are presented descriptively. Results: Highest any-grade incidence of abemaciclib-associated AEs across trials include diarrhea (82-90%), fatigue (41-65%), nausea (30-64%) and neutropenia (37-50%). Notable AEs leading to dose reduction, omission and discontinuation were: diarrhea (14-21%; 15-24%; 1-5%), neutropenia (8-13%; 16-17%; 1-3%), and fatigue (5%; 5%; 2%) respectively. In the monarchE trial, discontinuations due to AEs were highest in the first month and stabilized after 6 months. AE monitoring and management are presented in Table. Conclusions: Appropriate AE monitoring, symptom management strategies, and patient counseling should be used to manage AEs with a goal to impact early discontinuation of abemaciclib.[Table: see text]" @default.
- W4298139273 created "2022-10-01" @default.
- W4298139273 creator A5056237348 @default.
- W4298139273 creator A5074832732 @default.
- W4298139273 creator A5090188675 @default.
- W4298139273 date "2022-10-01" @default.
- W4298139273 modified "2023-09-24" @default.
- W4298139273 title "An overview of adverse event (AE) management for patients (pts) receiving abemaciclib." @default.
- W4298139273 doi "https://doi.org/10.1200/jco.2022.40.28_suppl.239" @default.
- W4298139273 hasPublicationYear "2022" @default.
- W4298139273 type Work @default.
- W4298139273 citedByCount "0" @default.
- W4298139273 crossrefType "journal-article" @default.
- W4298139273 hasAuthorship W4298139273A5056237348 @default.
- W4298139273 hasAuthorship W4298139273A5074832732 @default.
- W4298139273 hasAuthorship W4298139273A5090188675 @default.
- W4298139273 hasConcept C121608353 @default.
- W4298139273 hasConcept C126322002 @default.
- W4298139273 hasConcept C143998085 @default.
- W4298139273 hasConcept C197934379 @default.
- W4298139273 hasConcept C2777054765 @default.
- W4298139273 hasConcept C2777063308 @default.
- W4298139273 hasConcept C2777176818 @default.
- W4298139273 hasConcept C2778715236 @default.
- W4298139273 hasConcept C2778850193 @default.
- W4298139273 hasConcept C2780482068 @default.
- W4298139273 hasConcept C2780580376 @default.
- W4298139273 hasConcept C29730261 @default.
- W4298139273 hasConcept C530470458 @default.
- W4298139273 hasConcept C71924100 @default.
- W4298139273 hasConceptScore W4298139273C121608353 @default.
- W4298139273 hasConceptScore W4298139273C126322002 @default.
- W4298139273 hasConceptScore W4298139273C143998085 @default.
- W4298139273 hasConceptScore W4298139273C197934379 @default.
- W4298139273 hasConceptScore W4298139273C2777054765 @default.
- W4298139273 hasConceptScore W4298139273C2777063308 @default.
- W4298139273 hasConceptScore W4298139273C2777176818 @default.
- W4298139273 hasConceptScore W4298139273C2778715236 @default.
- W4298139273 hasConceptScore W4298139273C2778850193 @default.
- W4298139273 hasConceptScore W4298139273C2780482068 @default.
- W4298139273 hasConceptScore W4298139273C2780580376 @default.
- W4298139273 hasConceptScore W4298139273C29730261 @default.
- W4298139273 hasConceptScore W4298139273C530470458 @default.
- W4298139273 hasConceptScore W4298139273C71924100 @default.
- W4298139273 hasFunder F4320307758 @default.
- W4298139273 hasIssue "28_suppl" @default.
- W4298139273 hasLocation W42981392731 @default.
- W4298139273 hasOpenAccess W4298139273 @default.
- W4298139273 hasPrimaryLocation W42981392731 @default.
- W4298139273 hasRelatedWork W1875902782 @default.
- W4298139273 hasRelatedWork W1971495097 @default.
- W4298139273 hasRelatedWork W2104761597 @default.
- W4298139273 hasRelatedWork W2117609882 @default.
- W4298139273 hasRelatedWork W2528959283 @default.
- W4298139273 hasRelatedWork W2897627387 @default.
- W4298139273 hasRelatedWork W3036882192 @default.
- W4298139273 hasRelatedWork W3047145206 @default.
- W4298139273 hasRelatedWork W4233466023 @default.
- W4298139273 hasRelatedWork W2183331092 @default.
- W4298139273 hasVolume "40" @default.
- W4298139273 isParatext "false" @default.
- W4298139273 isRetracted "false" @default.
- W4298139273 workType "article" @default.